BWLPGConfluence between rising wedge and resistance at a 47.00. Strong reject.
Could retest rising support line before next breakout attempted.
Long at breakthrough of resistance at 47.
#SoftOx closer to a possible breakthrough against #covid19The Danish Medicines Agency has given its recommendation for further development of the SoftOx inhalation solution for the treatment of respiratory infections, including COVID-19.
The SoftOx Inhalation Project aims to develop an inhalation solution for the treatment of respiratory infections. This has the potential to be a breakthrough in the treatment of respiratory infections including Covid-19 infections. Following a scientific advisory meeting with the Danish Medicines Agency, a favorable development path has been suggested to be able to start testing in humans as soon as possible.
- It is now expected that the first studies in humans can start as early as the second quarter of 2021. SoftOx will therefore immediately start preparations to provide the necessary documentation that involves further safety studies in animal models, says Geir Almås, CEO of SoftOx Solutions.
- The need for new solutions treating respiratory tract infections is significant, this is a market which with conservative estimates for the EU and the US is approximately 12 billion USD. The number can probably be doubled looking in a global perspective, continue Almås.
This technology is unique, it is simple, exceptionally effective and does not trigger resistance. The effect is also independent of possible new mutated variants, as recently reported for the Corona virus.
- My team and I believe that we are facing a breakthrough in the treatment of difficult infections, both viral and bacterial. We have tested SoftOx solutions in the respiratory tract and we see that this can be an important treatment principle that can help fight the ongoing pandemic and future epidemics and pandemics ", says Professor of Microbiology and trial leader Thomas Bjarnsholt at the University of Copenhagen.
For more information contact:
Professor Thomas Bjarnsholt; tbjarnsholt@sund.ku.dk +45 206 59 888
CEO Geir Almås; geir.almaas@soft-ox.com +47 977 59 071
Professor Thomas Bjarnsholt is a member of the company's Scientific Advisory Board and has 20.000 stock options in SoftOx Solutions.
ArcticZymes $AZT Q3 2020 reportHighlights for Q3 2020
• Annual group sales exceed 100 MNOK for the first time
• Gross profit for the Group improved 65% to NOK 26.0 million (Q3 2019: NOK 15.7 million)
• ArcticZymes had Q3 sales of NOK 19.5 million growing by 63% (Q3 2019: NOK 12.0 million)
• Biotec BetaGlucans had Q3 sales of NOK 11.2 million growing by 7% (Q3 2019: NOK 10.5 million)
• Upsides relating to COVID-19 pandemic is estimated at NOK 4 million for ArcticZymes and NOK 1.25 million for consumer health
• The Group delivered positive EBITDA with NOK 10.1 million (Q3 2019: NOK 0.8 million)
• Cash-flow for Q3 was positive NOK 13.6 million (Q3 2019: NOK 0.7 million) giving a cash balance of NOK 69.7 million (Q3 2019: NOK 22.1 million)
Lifecare Long (daughter company worth 4x as much)This analysis isn't as based on techincal indicators as it is on market insight. As far as the technical signs go, RSI and stochastic RSI show that it is significantly underbought. The appearance of an ascending triangle formation is also noticable, with high potential gains if it breaks up. The most interesting find is that Lifecare has ownership in Digital Diagnostics (a company which has come far within Covid-19 testing) worth over 4x as much as the Lifecare valuation itself. This coupled with the fact that Lifecare has conducted successful sensor technology testing for Diabetes, and it being the only commercial actor in this consortium, could potentially take this company to new heights.
Awilco long (increasing LNG prices)Awilco bottomed out recently and seems to be in a short term bullish channel. Techincal indicators such as short term MAs crossing up coupled with rising LNG (liquified natural gas) prices solidify this trend.
Ultimovacs Announces Updated Positive Results from Phase I TrialOslo, 19 October 2020: Ultimovacs ASA ("Ultimovacs", ticker ULTIMO), today
announced five-year overall survival data from the Phase I trial evaluating UV1
as maintenance therapy in patients with non-small cell lung cancer. The results
confirm achievement of the primary endpoints of safety and tolerability and
indicate encouraging initial signals of long-term survival benefit.
"Ultimovacs has established a growing body of clinical data demonstrating a
strong safety and tolerability profile for UV1 and a range of preliminary
efficacy signals in several cancer indications, all of which supports the
further development of our proprietary cancer vaccine candidate," stated Carlos
de Sousa, Chief Executive Officer at Ultimovacs. "The long-term follow-up
results announced today demonstrate that treatment with UV1 is safe both at the
time of administration and throughout the follow-up period of at least 5 years.
Non-small cell lung cancer highly expresses telomerase and remains an indication
in great need of new treatment options for patients."
In the study, a total of 18 non-small cell lung cancer patients whose disease
had not progressed after receiving at least 2nd line treatment with chemotherapy
were enrolled to receive UV1 monotherapy as maintenance treatment. Outcomes of
the study included the safety and tolerability of UV1 as well as initial signs
of clinical response. As per the cut-off date of June 2020, every patient in the
trial reached at least 60-months of follow-up post treatment with UV1. At the
five-years landmark, the Overall Survival (OS) rate was 33% and median
Progression Free Survival (mPFS) was 10.7 months. Throughout the follow-up
period, none of the patients experienced unexpected safety issues related to
UV1. Further, none of the patients alive after 5 years have received other
immunotherapy after the vaccination with UV1.
"At the time of the study initiation, there were no checkpoint inhibitors
available for treatment of this patient population. For patients that received a
second-line of chemotherapy the expected 5-year survival rate was less than 5
percent," stated Jens Bjørheim, Chief Medical Officer at Ultimovacs. "While our
Phase I study is non-randomized and conducted in a small population, it is
promising to see that UV1 was safe and well-tolerated and that using UV1 as a
maintenance therapy could potentially provide benefit to patients in need of
novel approaches."
Ultimovacs presented 48-months of follow-up data at the Society for
Immunotherapy of Cancer's (SITC) 34th Annual Meeting in November of last year.
NODL long, short-term MAs moving up. Northern drilling seems to have bottomed out after an extended devaluation period. The stock has oscillated between 3 and 6 NOK for the past months and looks to have entered a bullish channel. Technical signals include a recent 10 and 20 MA crossing up in the 4 hour and 1 day intervals. The stock's potential ability to break out over its resistance levels at 5 and 6.7 NOK could indicate a longer bullish trend. Stochastic RSI and RSI indicate that the instrument is close to or overbought as of now. Operating revenue first six months of 2020 increased from last six months of 2019, however second quarter results decreased YoY compared to second quarter of 2019.
Market reconsidering previous valuation of Kitron $KIT Enthusiastic trading ahead of Kitrons Q3 report which is scheduled for October 20th
Asetek balancing on last supportRSI moving towards oversold
MACD bearish
Still long term uptrend
Upcoming Earnings.
Love to supply near 72.
Reversal might show next week.
Norwegian Air shuttle's potential - stock price down 99.72%Hello you all
As you know Norwegian Air Shuttle is a company which is heavely affected by the actual pandemic.
So why could the stock have a huge potential in the near/medium term future?
- Chinese government invested via BOC Aviation into Norwegian
- cash burn reduced to <300 million NOK per month
- current stock price 99.72% under all time high
Norwegian announced at the beginning of the pandemic, that there will be a liquidity risk from Q4 2020/Q1 2021. Norwegian is currently talking with the Norwegian government for another bailout. If that will be accepted, it could give the company money for another six month's or so, which means, that a bankruptcy is unlikely during that period of time. Chances of a higher stock price stands pretty good.
In my opinion it makes totally sence that the stock price went down heavely during this time. But 99.72% of all time highs?
Nevertheless, be careful, the company has a possibility to go bankrupt. Could go to zero.
Norwgian Air Shuttle (NAS)"The time to buy is when there's blood in the streets."
- Baron Rothschild
So if you are looking for said blood the Norwegian Air shuttle (NAS) might be worth a serious look.
Background:
Biggest airline company in Scandinavia. One of the biggest in the world (I believe Top 6).
It's based in Norway. Norway is a rich country. "Oil rich".
Like many other airline companies the company is suffering massive losses.
The state of Norway has already helped the company out a lot.
Pros:
As just mentioned Norway is rich, and I believe that the state will do everything in it's power to rescue the company. I believe the company will keep asking for more help until things get back to normal in 2022/2023.
Cons:
It's still a falling knife. Never catch a falling knife.
The company has been suffering pre-COVID-19 too.
The company has never been through this big a crisis. It could end up in bankrupcy this time. Know this if investing.
Technical analysis:
To hell with technical analysis at this point. All support has been broken.
I love TD sequentials though. Looking at the daily the TD countdown of 13 was reached monday and next monday could give us another 9 sell on the TD setup.
Be careful. Cheers
PCI Biotech $PCIB bullish breaching 100EMA coming into Q4* Norwegian Drug Delivery Platform Biotech operating within the Oslo Cancer Cluster
* Notoriously volatile norwegian small cap with large amount of stock held by enthusiastic retail investor crowd.
* Ongoing research collaboration with AstraZeneca recently concluded, longs betting on partnership deal incoming.
* Stock typically rallies ahead of quarterly reports and experiences sell the news events.
* Norwegian biotech flying at All Time High valuations after recent Vaccibody partnership with Genentech.
NAShumm only been down a year or so and 4-5 years ago was doing $148 - $220 a share till just this year. Fallen Angel?
$NEL Hydrogen testing breakout from short term downtrendNEL has become a trader favourite with recent volatility after Nikola was hit by short seller report.
Hourly 20 EMA breaking above 100 EMA, often seen as a promising momentum shift indicator.
NEL needs to break above support/resistance at about 18 and consolidate to regain a bullish sentiment in the short term.
Todays top 20 list show that the Clearstream crowd are still buying NEL stock like hot cakes, reducing fear that main investors would be dissuaded by recent price movements
